Stock Price Quote

KREBS BIOCHEMICALS & INDUSTRIES LTD.

NSE : KREBSBIOBSE : 524518ISIN CODE : INE268B01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE63.550 (0 %)
PREV CLOSE ( ) 63.55
OPEN PRICE ( ) 61.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 9
TODAY'S LOW / HIGH ( )61.00 63.55
52 WK LOW / HIGH ( )60.17 113.9
NSE62.70-1.1 (-1.72 %)
PREV CLOSE( ) 63.80
OPEN PRICE ( ) 63.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2612
TODAY'S LOW / HIGH( ) 60.81 63.80
52 WK LOW / HIGH ( )58.8 113.5
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 02-12 1991
Management Info
R T Ravi - Chairman Manish Jain - Managing Director
Registered Office

Address Kothapalli Village,Anakapalli,Kasimkota Mandal,
Vishakhapatnam,
Andhra Pradesh-531031

Phone 040-66808040 / 9121144984

Email marketing@krebsbiochem.com / com_sec@krebsbiochem.com

Website www.krebsbiochem.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

14Jan Krebs Biochemicals and Industries info
Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosur..
05Jan Krebs Biochemicals & Industries inform
In terms of SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 date..
02Jan Krebs Biochemicals & Industries inform
Krebs Biochemicals & Industries has informed that it enclosed certif..
18Nov Krebs Biochemicals & Industries infor
In terms of SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 date..
05Nov Krebs Biochemicals and Industries info
Krebs Biochemicals and Industries has informed that it enclosed copies o..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit-61.43-269.39
Gross Profit -61.43 -269.24
Operating Profit -27.86-143.21
Net Sales 41.67433.12

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  27829.85 (0.48%)
M.Cap ( in Cr)59136.49
Innova Captab (BSE)
peergroup  678.40 (3.27%)
M.Cap ( in Cr)3882.14
Alivus Life Sciences (BSE)
peergroup  882.10 (2.36%)
M.Cap ( in Cr)10826.57
Sudeep Pharma (BSE)
peergroup  560.15 (3.43%)
M.Cap ( in Cr)6326.82
Dr. Reddy's Lab (BSE)
peergroup  1235.15 (1.48%)
M.Cap ( in Cr)103089.37

Shareholding Pattern

PROMOTERS 72.74%
NON-INSTITUTION 26.76%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Krebs Biochemicals & Industries Ltd.

Krebs Biochemicals & Industries Ltd. was incorporated in the year 1991. Its today's share price is 63.55. Its current market capitalisation stands at Rs 135.18 Cr. In the latest quarter, company has reported Gross Sales of Rs. 433.12 Cr and Total Income of Rs.440.21 Cr. The company's management includes Sumanth Karlapudi, Satya Prakash Chigurupati, Dipti Shah, PM Kathariya, Avinash Ravi, Pabitra Bhattacharya, Manish Jain, R T Ravi, Rakesh Kalbate.

It is listed on the BSE with a BSE Code of 524518 , NSE with an NSE Symbol of KREBSBIO and ISIN of INE268B01013. It's Registered office is at Kothapalli Village,Anakapalli,Kasimkota MandalVishakhapatnam-531031, Andhra Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Bhavani & Co, Pavuluri & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.